Home Products About Us Contact

Chromogenic Kits

Learn more about our Chromogenic Kits.

Phospholipid Emulsions

Our highly stable phospholipid emulsions are suitable for use in analyses related to procoagulant and anticoagulant pathways.



Rossix is a company devoted to Thrombosis and Hemostasis. The company represents the experience of more than 30 years of development work in the field. 


Rossix provides Products for use in Hemostasis Research and Quality Control. The vast majority of our customers are pharmaceutical companies and academic bioscience laboratories.

Rox Factor XIa

REF 110050

A chromogenic kit for quantitative activity determination of Factor XIa in enriched or highly purified protein preparations.

Use together with Factor XIa Calibrator and Control assigned in U/ml against the first NIBSC reference reagent, 11/236.

Rox Factor IX - CE

REF 900020

Our chromogenic kit for quantitative activity determination of Factor IX is CE marked and 

approved for In Vitro Diagnostic Use in Europe.

Outside Europe the Rox Factor IX kit is available for research use.

Where to Buy?

In a number of countries, Rossix has local distributors which are specialized in the field of Thrombosis and Hemostasis.

For other countries Rossix sells directly to end users:


2018-06-29 Posters at the SSC meeting in Dublin July 18-21, 2018.

Steffen Rosén and Rossix AB will present two posters at the SSC meeting in Dublin:

PB229 - Overestimation of recombinant wild type FIX potency by a one-stage method indicated from comparison with a chromogenic FXIa and TF/FVIIa based methods and through discrepant activation of rwtFIX and plasma derived FIX by plasma kallikrein.

PB238 - Underassignment of FIX potency of rFIX-Albumin fusion protein by one-stage methods demonstrated in studies on FXIa and FIXa generation. 


2016-06-22 Publication in collaboration with NovoNordisk

Rosén P, Rosén S, Ezban M, Persson E.

Overestimation of N-glycoPEGylated factor IX activity in one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.

J Thromb Haemost 2016; 14: 1420-7.


2015-04-13 Publication in collaboration with AstraZeneca

Ann Lövgren et al. Blood Coagulation and Fibrinolysis, Characterization of thrombin derived from 

human recombinant prothrombin.

Open access: click here